دورية أكاديمية
Genicular Artery Embolization for Treatment of Knee Osteoarthritis: Interim Analysis of a Prospective Pilot Trial Including Effect on Serum Osteoarthritis-Associated Biomarkers.
| العنوان: | Genicular Artery Embolization for Treatment of Knee Osteoarthritis: Interim Analysis of a Prospective Pilot Trial Including Effect on Serum Osteoarthritis-Associated Biomarkers. |
|---|---|
| المؤلفون: | Taslakian B; Division of Vascular and Interventional Radiology, Department of Radiology, NYU Langone Health, New York, New York. Electronic address: bedros.taslakian@nyulangone.org., Swilling D; Division of Vascular and Interventional Radiology, Department of Radiology, NYU Langone Health, New York, New York., Attur M; Division of Rheumatology, Department of Medicine, NYU Langone Health, New York, New York., Alaia EF; Division of Vascular and Interventional Radiology, Department of Radiology, NYU Langone Health, New York, New York; Division of Musculoskeletal Imaging, Department of Radiology, NYU Langone Health, New York, New York., Kijowski R; Division of Vascular and Interventional Radiology, Department of Radiology, NYU Langone Health, New York, New York; Division of Musculoskeletal Imaging, Department of Radiology, NYU Langone Health, New York, New York., Samuels J; Division of Rheumatology, Department of Medicine, NYU Langone Health, New York, New York., Macaulay W; Department of Orthopedic Surgery, NYU Langone Health, New York, New York., Ramos D; Division of Vascular and Interventional Radiology, Department of Radiology, NYU Langone Health, New York, New York., Liu S; Division of Vascular and Interventional Radiology, Department of Radiology, NYU Langone Health, New York, New York., Morris EM; Division of Vascular and Interventional Radiology, Department of Radiology, NYU Langone Health, New York, New York., Hickey R; Division of Vascular and Interventional Radiology, Department of Radiology, NYU Langone Health, New York, New York. |
| المصدر: | Journal of vascular and interventional radiology : JVIR [J Vasc Interv Radiol] 2023 Dec; Vol. 34 (12), pp. 2180-2189.e3. Date of Electronic Publication: 2023 Aug 26. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Society of Cardiovascular and Interventional Radiology Country of Publication: United States NLM ID: 9203369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1535-7732 (Electronic) Linking ISSN: 10510443 NLM ISO Abbreviation: J Vasc Interv Radiol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Reston, Va. : Society of Cardiovascular and Interventional Radiology, c1990- |
| مواضيع طبية MeSH: | Osteoarthritis, Knee*/diagnostic imaging , Osteoarthritis, Knee*/therapy, Humans ; Prospective Studies ; Pilot Projects ; Nerve Growth Factor/therapeutic use ; Treatment Outcome ; Pain |
| مستخلص: | Purpose: To characterize the safety, efficacy, and potential role of genicular artery embolization (GAE) as a disease-modifying treatment for symptomatic knee osteoarthritis (OA). Materials and Methods: This is an interim analysis of a prospective, single-arm clinical trial of patients with symptomatic knee OA who failed conservative therapy for greater than 3 months. Sixteen patients who underwent GAE using 250-μm microspheres and had at least 1 month of follow-up were included. Six patients completed the 12-month follow-up, and 10 patients remain enrolled. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) was evaluated at baseline and at 1, 3, and 12 months. Serum and plasma samples were collected for biomarker analysis. The primary end point was the percentage of patients who achieved the minimal clinically important difference (MCID) for WOMAC pain score at 12 months. Baseline and follow-up outcomes were analyzed using the Wilcoxon matched-pairs signed-rank test. Results: Technical success of the procedure was 100%, with no major adverse events. The MCID was achieved in 5 of the 6 (83%) patients at 12 months. The mean WOMAC pain score decreased from 8.6 ± 2.7 at baseline to 4.9 ± 2.7 (P = .001), 4.4 ± 2.8 (P < .001), and 4.7 ± 2.7 (P = .094) at 1, 3, and 12 months, respectively. There was a statistically significant decrease in nerve growth factor (NGF) levels at 12 months. The remaining 8 biomarkers showed no significant change at 12 months. Conclusions: GAE is a safe and efficacious treatment for symptomatic knee OA. Decreased NGF levels after GAE may contribute to pain reduction and slowing of cartilage degeneration. (Copyright © 2023 SIR. Published by Elsevier Inc. All rights reserved.) |
| المشرفين على المادة: | 9061-61-4 (Nerve Growth Factor) |
| تواريخ الأحداث: | Date Created: 20230828 Date Completed: 20231128 Latest Revision: 20240205 |
| رمز التحديث: | 20240205 |
| DOI: | 10.1016/j.jvir.2023.08.029 |
| PMID: | 37640104 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder كن أول من يترك تعليقا!